Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desomorphine is a semi-synthetic opioid analgesic first synthesized in the United States in 1932 and briefly marketed by Hoffman-LaRoche under the brand name Permonid for post-operative pain. It is a morphinane alkaloid and a derivative of morphine with modifications that make it more lipophilic and about 8–10 times more potent than morphine. Desomorphine acts primarily as a mu-opioid receptor agonist with less activity at kappa- and delta-opioid receptors. It has a faster onset of action and shorter duration compared to morphine but carries an increased risk of dependence, respiratory depression, hypotension, urinary retention, and other side effects. Medical use was discontinued due to its high addictive potential and severe adverse effects. In recent years, illicitly produced desomorphine—commonly known as "krokodil"—has been used recreationally as a cheap heroin substitute; this form is often contaminated with toxic byproducts leading to severe tissue damage at injection sites[1][3][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desomorphine.